

Curriculum Vitae – Karl Andersen

Karl Andersen

MD PhD FESC

Professor of Cardiology

Landspítali, the University Hospital of Iceland, Reykjavík IS-101
Icelandic Heart Association, Kópavogi, IS-201

Contact: [email](#)



**National CVD Prevention
Coordinator for Iceland**

Short CV

Dr Karl Andersen is a Cardiologist and specialist in Internal Medicine.

He is Professor of Cardiology at the Faculty of Medicine, University of Iceland and Head of the Cardiac Emergency Department at Landspítali University Hospital in Reykjavik.

He is Director of the Risk Assessment Clinic and a Board member of the Icelandic Heart Association.

He is Chair of the Cardiovascular Research Centre at Landspítali University Hospital and University of Iceland. He is past president of the Icelandic Society of Cardiology.

Dr Andersen has served on several Faculty committees.

He is Fellow of the ESC and a member of the European Affairs Committee of the European Society of Cardiology and was recipient of the European Health Award 2010 by the European Health Forum, Gastein as a member of the European Chronic Disease Alliance.

Dr Andersen is on the Steering Committee of several international clinical trials.

He currently serves on an advisory committee on tobacco control to the Directorate of Health in Iceland and is a member of the Icelandic Science and Technology Policy Council.

Dr Andersen defended his doctoral thesis at the University of Gothenburg, Sweden in 1997.

He has published over 200 scientific papers and abstracts on clinical cardiology.

Addendum to Karl Andersen's Curriculum Vitae

Selected Publications

1. Hakonarson H, Thorvaldsson S, Helgadóttir A, Gudbjartsson D, Zink F, Andresdóttir M, Manolescu A, Arnar DO, Andersen K, Sigurdsson A, Thorgeirsson G, Jonsson A, Agnarsson U, Bjornsdóttir H, Gottskalksson G, Einarsson A, Gudmundsdóttir H, Adalsteinsdóttir AE, Gudmundsson K, Kristjansson K, Hardarson T, Kristinsson A, Topol EJ, Gulcher J, Kong A, Gurney M, Thorgeirsson G, Stefansson K.
Effects of a 5-lipoxygenase-Activating Protein Inhibitor on Biomarkers Associated With Risk of Myocardial Infarction. A Randomized Trial.
JAMA 2005;293:2245-56.
2. Jónsdóttir S, Andersen K, Sigurdsson AS, Sigurdsson SB.
The effect of physical training in chronic heart failure.
The European Journal of Heart Failure 2006;8:97-101.
3. Helgadóttir A, Thorleifsson G, Manolescu A, Gretarsdóttir S, Blondal T, Jonasdóttir A, Sigurdsson A, Baker A, Palsson A, Masson G, Gudbjartsson D, Magnusson KP, Andersen K, Levey AI, Beckman VM, Matthiasdóttir S, Jonsdóttir T, Palsson S, Einarsdóttir H, Gunnarsdóttir S, Gylfason A, Vaccarino V, Hooper WC, Reilly MP, Granger CB, Austin H, Rader DJ, Shah SH, Quyyumi AA, Gulcher JR, Thorgeirsson G, Thorsteinsdóttir U, Kong A, Stefansson K.
A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction.
Science 2007;316:1491-3.
4. Helgadóttir A, Thorleifsson G, Magnusson KP, Gretarsdóttir S, Steinthorsdóttir V, Manolescu A, Jones GT, Rinkel GJE, Blankensteijn Jd, Ronkainen A, Jääskelinen JE, Kyo Y, Lenk GM, Sakalihasan N, Kostulas K, Gottsäter A, Flex A, Stefansson H, Hansen T, Andersen G, Weinsheimer S, Borch-Johnsen K, Jorgensen T, Shah SH, Quyyumi AA, Granger CB, Reilly MP, Austin H, Levey AI, Vaccarino V, Palsdóttir E, Walters GB, Jonsdóttir Th, Snorraddóttir S, Magnusdóttir D, Gudmundsson G, Ferrell RE, Sveinbjornsdóttir S, Hernesniemi J, Niemelä M, Limet R, Andersen K, Sigurdsson G, Benediktsson R, Verhoeven ELG, Teijink JAW, Grobbee DE, Rader DJ, Collier DA, Pedersen O, Pola R, Hillert J, Lindblad B, Valdimarsson E, Magnadóttir HB, Wijmenga C, Tromp G, Baas AF, Ruigrok YM, van Rij, AM, Kuivaniemi H, Powell JT, Matthiasson SE, GulcherJR, Thorgeirsson G, Kong A, Thorsteinsdóttir U, Stefansson K.
The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm.
Nature Genetics 2008;40:217-224.
5. Andersen K, Weinberger M, Egan B, Constance C, Ali MA, Jin J, Keefe DL.
Comparative efficacy and safety of oral aliskiren, an oral direct renin inhibitor, and ramipril in patients with hypertension: a 6-month, randomized, double-blind trial.
J Hypertension 2008;25:589-599.
6. Andersen K.
Renin-Angiotensin System in the Elderly-Rational use of Aliskiren in Managing Hypertension.
Clin Interv Aging 2009;4:137-151.
7. Andersen K, Weinberger MH, Constance CM, Ali MA, Jin J, Prescott MF, Keefe DL.
Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
J Renin Angiotensin Aldosterone Syst 2009;10(3):157-167
8. Andersen K, Steinþórsdóttir SD, Haraldsdóttir S, Gudnason Th.

Clinical evaluation and stress test have limited value in the diagnosis of in-stent restenosis.

Scandinavian Cardiovascular Journal 2009;6:402-407

9. Haraldsdottir S, Gudnason Th, Sigurdsson AF, Gudjonsdottir J, Lehman S, Eyjolfsson K, Scheving SS, Gibson MC, Hoffmann U, Jonsdottir B, Andersen K.
Diagnostic Accuracy of 64-Slice Multidetector CT for Detection of In-Stent Restenosis in an Unselected, Consecutive Population.
Eur J Radiol 2010;76:188-194.
10. Aspelund Th, Gudnason V, Magnusdottir BT, Andersen K, Sigurdsson G, Thorsson B, Steingrimsdottir L, Critchley J, Bennet K, O'Flaherty M, Capewell S.
Analysing the Large Decline in Coronary Heart Disease Mortality in the Icelandic Population Aged 25-74 Between the Years 1981 and 2006: Contributions from Major Risk Facotors.
PLoS ONE,2010;5(11):e13957.doi:10.1371/journal.pone.0013957
11. Andersen K, Johannesdottir BK, Kristjansson JM, Gudnason Th.
Decreasing case fatality in myocardial infarction is explained by improved medical treatment.
Acta Cardiologica 2011;66(1):39-45.
12. Ganesh SK, Joo J, Skelding K, Mehta L, Zheng G, O'Neill K, Billings EM, Helgadottir A, Andersen K, Geller NL, Simari RD, Holmes DR, O'Neill WW, Nabel EG.
Time course analysis of gene expression identifies multiple genes with differential expression in patients with in-stent restenosis.
BMC Med Genomics 2011 Feb 28;4:20
13. Schunkert H, König IR, Kathiresan K, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AFR, Barbalic M, Gieger C, Absher D, Aherrahrou Z, Allayee H, Altshuler D, Anand SS, **Andersen K**, Anderson JL, Ardissino D, Ball SG, Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boekholdt SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buyschaert I, Carlquist JF, Chen L, Codd V, Davies RW, Dedoussis G, Dehghan A, Demissie S, Devaney JM, Do R, Doering A, El Mokhtari N E, Ellis SG, Elosua R, Engert JC, Epstein SE, Eifert S, de Faire U, Fischer M, Folsom AR, Freyer J, Gigante B, Girelli D, Gretarsdottir S, Gudnason V, Gulcher JR, Gulde S, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJP, Khaw K-T, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Lettre G, Li M, Lieb W, Linsel-Nitschke P, Loley C, Lotery AJ, Mannucci PM, Maouche S, Martinelli N, McKeown PP, Meisinger C, Meitinger T, Melander O, Merlini PA, Mooser V, Morgan T, Muhlestein TW, Cichon S, Muhlestein JB, Münzel T, Musunuru K, Nahrstaedt J, Nelson CP, Nöthen MM, Olivieri O, Peyvandi F, Patel RS, Patterson CC, Peters A, Qu L, Quyyumi AA, Rader DJ, Rallidis LS, Rice C, Rosendaal FR, Rubin D, Salomaa V, Sampietro ML, Sandhu MS, Schadt E, Schäfer A, Schillert A, Schreiber S, Schrezenmeir J, Schwart SM, Siscovick DS, Sivanathan M, Sivapalarnatam S, Smith A, Smith TB, Snoop JD, Soranzo N, Spertus JA, Stark K, Stirrups K, Stoll M, Tang WHW, Thorgeirsson G, Thorleifsson G, Tomaszewski M, Uitterlinden AG, van Rij AM, Voight BF, Wareham NJ, Wells GA, Wichmann H-E, Wild PS, Willenborg C, Witterman JCM, Wright BJ, Ye S, Zeller T, Ziegler A, Cambien f, Goodall AH, Cupples LA, Quertermous T, März W, Hengstenberg C, Blankenberg S, Ouwehand W, Hall AS, Deloukas P, Thompson JR, Stefansson K, Roberts R, Thorsteinsdottir U, O'Donnell CJ, McPherson R, Erdmann J Samani NJ, for the **CARDIoGRAM Consortium.**
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease.
Nature Genetics 2011;Mar 6. 43(4):333-8
14. O'Kelly S, Andersen K, Capewell S, Rydén L.
Bringing Prevention to the Population.
Eur Heart J 2011;32(16):1964-7. Epub 2011 May 26

15. Capewell S, Andersen K.
The ESC goes global. Policies to prevent all chronic diseases. The alarming increase in global NCDs is stimulating efforts to tackle the burden on national levels.
Eur Heart J 2011; 32:2333-2340.
16. Andersen K, Hartman D, Peppard T, Hermann D, Van Ess P, Lefkowitz M, Trapani A.
The effects of Aldosterone Synthase Inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo controlled, multicenter study.
J Clin Hypertens (Greenwich) 2012 Sept;14(9):580-7. doi: 10.1111/j.1751-7176.2012.00667.x
17. Gudnason T, Gudnadottir GS, Lagerqvist B, Eyjolfsson K, Nilsson T, Thorgeirsson G, Thorgeirsson G, Andersen K, James S.
Comparison of interventional cardiology in two European countries: A nationwide internet based registry study.
Int J Cardiol(2012), <http://dx.doi.org/10.1016/j.ijcard.2012.11.054>
18. Thorsson B, Steingrimsdottir L, Aspelund T, Halldorsdottir S, Andersen K, Sigurdsson G, Aspelund T, Gudnason V.
Changes in total cholesterol levels in Western societies are not related to statin, but rather dietary factors: the example of the Icelandic population.
Eur Heart J 2013;34:1778-1782
19. Andersen K.
Aldosterone synthase inhibition in hypertension.
Curr Hypertens Rep. 2013 Oct;15(5):484-8. doi: 10.1007/s11906-013-0379-7.
20. Thorolfsson RB, Aspelund T, Capewell S, Critchley J, Gudnason V, Andersen K.
Population assessment of future projectories in coronary heart disease mortality.
PLoS ONE 2013, in press